Effects of hormonal replacement treatment on bone mineral density and metabolism in hypogonadal patients
- PMID: 10773391
- DOI: 10.1016/s0303-7207(99)00223-3
Effects of hormonal replacement treatment on bone mineral density and metabolism in hypogonadal patients
Abstract
We investigated 22 male patients affected by prepubertal hypogonadism with a mean age of 34.3+/-5.2. A significant reduction of bone mineral density (BMD) at both the lumbar spine (L2-L4, -14%, 1.039+/-0.11 vs. 1.217+/-0.16 g/cm(2), P=0.005) and femoral neck (-11%; 0.927+/-0.09 vs. 1.034+/-0.16 g/cm(2), P=0.01) was found in patients compared to age-matched controls. The mean Z score was -1. 55 for vertebrae and -1.33 for femur. Eleven and nine patients, respectively, had a lumbar and femoral BMD at least 1 S.D. below the normal mean; 8 and 4, respectively, 2 S.D. below. There was a strong positive correlation between BMD and duration of hormone replacement treatment (HRT) for both sites: respectively, r=0.71, P<0.005 for the vertebrae, and r=0.60, P<0.01 for the femur. A weak correlation was also present between onset of HRT and BMD: r=0.6, P<0.01 at the lumbar level, and r=0.47, P<0.05 at the femoral neck.
Similar articles
-
Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome.Endocrine. 2018 Aug;61(2):327-335. doi: 10.1007/s12020-018-1604-6. Epub 2018 Apr 25. Endocrine. 2018. PMID: 29696556
-
Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.Aging Male. 2012 Jun;15(2):96-102. doi: 10.3109/13685538.2011.631230. Epub 2012 Mar 23. Aging Male. 2012. PMID: 22439807 Clinical Trial.
-
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.Clin Endocrinol (Oxf). 2000 Mar;52(3):319-27. doi: 10.1046/j.1365-2265.2000.00902.x. Clin Endocrinol (Oxf). 2000. PMID: 10718830
-
Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.Asian J Androl. 2002 Jun;4(2):117-21. Asian J Androl. 2002. PMID: 12085102
-
Testosterone supplementation and bone parameters: a systematic review and meta-analysis study.J Endocrinol Invest. 2022 May;45(5):911-926. doi: 10.1007/s40618-021-01702-5. Epub 2022 Jan 18. J Endocrinol Invest. 2022. PMID: 35041193 Review.
Cited by
-
Testosterone therapy in children and adolescents: to whom, how, when?Int J Impot Res. 2022 Nov;34(7):652-662. doi: 10.1038/s41443-021-00525-5. Epub 2022 Jan 7. Int J Impot Res. 2022. PMID: 34997199 Review.
-
Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health.Int J Endocrinol. 2017;2017:4602129. doi: 10.1155/2017/4602129. Epub 2017 Mar 16. Int J Endocrinol. 2017. PMID: 28408926 Free PMC article. Review.
-
Effects of short-term testosterone replacement on areal bone mineral density and bone turnover in young hypogonadal males.Indian J Endocrinol Metab. 2012 Nov;16(6):947-51. doi: 10.4103/2230-8210.102997. Indian J Endocrinol Metab. 2012. PMID: 23226640 Free PMC article.
-
Androgen replacement therapy in the aging male.Rev Urol. 2003 Fall;5(4):216-26. Rev Urol. 2003. PMID: 16985841 Free PMC article.
-
Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment.J Endocrinol Invest. 2001 Apr;24(4):246-52. doi: 10.1007/BF03343854. J Endocrinol Invest. 2001. PMID: 11383911 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical